KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Leases (2019 - 2026)

Esperion Therapeutics filings provide 7 years of Current Leases readings, the most recent being $2.1 million for Q4 2025.

  • On a quarterly basis, Current Leases fell 23.31% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 23.31% decrease, with the full-year FY2025 number at $2.1 million, down 23.31% from a year prior.
  • Current Leases hit $2.1 million in Q4 2025 for Esperion Therapeutics, down from $2.4 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.8 million in Q1 2025 to a low of $305000.0 in Q1 2023.
  • Median Current Leases over the past 5 years was $2.2 million (2021), compared with a mean of $1.8 million.
  • Biggest five-year swings in Current Leases: tumbled 74.94% in 2023 and later surged 732.46% in 2024.
  • Esperion Therapeutics' Current Leases stood at $1.4 million in 2021, then crashed by 72.41% to $384000.0 in 2022, then soared by 304.43% to $1.6 million in 2023, then skyrocketed by 76.5% to $2.7 million in 2024, then fell by 23.31% to $2.1 million in 2025.
  • The last three reported values for Current Leases were $2.1 million (Q4 2025), $2.4 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.